Page last updated: 2024-11-06

fluproquazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Fluproquazone is a non-steroidal anti-inflammatory drug (NSAID) that was initially developed for the treatment of rheumatoid arthritis. It is a potent inhibitor of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins. Prostaglandins are involved in pain, inflammation, and fever. Fluproquazone was withdrawn from the market in 1993 due to concerns about its potential hepatotoxicity (liver toxicity). However, it continues to be studied for its potential therapeutic effects in other conditions, such as cancer and Alzheimer's disease. It is currently being studied for its effects on cancer cell growth and proliferation. Fluproquazone is also being investigated for its potential to reduce the risk of developing Alzheimer's disease. The compound is also known to be a potent anti-inflammatory agent and has been shown to be effective in treating a variety of inflammatory conditions.'

fluproquazone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID38503
CHEMBL ID2106681
SCHEMBL ID26210
MeSH IDM0080792

Synonyms (36)

Synonym
2(1h)-quinazolinone, 4-(p-fluorophenyl)-1-isopropyl-7-methyl-
4-fluorphenyl-1-isopropyl-7-methyl-2(1h)-chinazolinon [german]
brn 0891838
fluproquazonum [inn-latin]
2(1h)-quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)-
sah 46-790
rf 46-790
4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)-2(1h)-quinazolinone
4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1h)-quinazolinone
fluproquazona [inn-spanish]
1-isopropyl-7-methyl-4-(p-fluorophenyl)-2(1h)-quinazolinone
fluproquazone
tormosyl
D04229
fluproquazone (usan/inn)
40507-23-1
tormosyl (tn)
4-(4-fluorophenyl)-7-methyl-1-propan-2-ylquinazolin-2-one
CHEMBL2106681
fluproquazona
fluproquazone [usan:inn:ban]
u4k85o58hd ,
fluproquazonum
unii-u4k85o58hd
4-fluorphenyl-1-isopropyl-7-methyl-2(1h)-chinazolinon
fluproquazone [usan]
fluproquazone [mi]
fluproquazone [inn]
SCHEMBL26210
1-isopropyl-4-(4-fluorophenyl)-7-methyl-2(1h)-quinazolinone
ZWOUXWWGKJBAHQ-UHFFFAOYSA-N
DTXSID70193519
Q5462887
rf 46-790;sah 46-790;tormosyl
4-(4-fluorophenyl)-1-isopropyl-7-methylquinazolin-2(1h)-one
AKOS040746839

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The metabolite pattern did not vary significantly among the 3 human subjects analyzed nor over the 5-day dosing period."( The biotransformation of fluproquazone in man and several animal species.
Bhuta, SI; Dugger, HA; Orwig, BA; Schwarz, HJ; Talbot, KC, 1981
)
0.57
" Both dosage were well tolerated during the short-term trial."( Fluproquazone in the management of strains and sprains.
Jaegemann, V; Kolb, E; Lataste, X; Pabst, J, 1981
)
1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1712996Selectivity for COX-2 (unknown origin) over COX-1 (unknown origin)2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (96.15)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (3.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (53.85%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (46.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]